pioglitazone has been researched along with Peritonitis in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 5.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 1.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandez-Boyanapalli, R | 1 |
| Frasch, SC | 1 |
| Riches, DW | 1 |
| Vandivier, RW | 1 |
| Henson, PM | 1 |
| Bratton, DL | 1 |
| Tsujimura, Y | 1 |
| Matsutani, T | 1 |
| Matsuda, A | 1 |
| Kutsukake, M | 1 |
| Uchida, E | 1 |
| Sasajima, K | 1 |
| Tamura, K | 1 |
2 other studies available for pioglitazone and Peritonitis
| Article | Year |
|---|---|
PPARĪ³ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease.
Topics: Animals; Cytokines; Gene Deletion; Gene Expression Regulation; Granulomatous Disease, Chronic; Human | 2010 |
Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.
Topics: Adipocytes; Adiponectin; Animals; Cecum; Chemokine CCL2; Disease Models, Animal; Gene Expression; Hy | 2011 |